Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-148a-3p LNA
- Development stage
- Preclinical
- Lead developer
- Lund University
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, Intratumoral, Intravenous, Subcutaneous
01
Overview
miR-148a-3p LNA is a locked nucleic acid (LNA)-modified antisense oligonucleotide designed to target and inhibit microRNA-148a-3p (miR-148a-3p). In preclinical models of type 2 diabetes, silencing of miR-148a-3p using this LNA-modified inhibitor has been shown to enhance glucose-stimulated insulin secretion in pancreatic beta-cells. Beyond diabetes, miR-148a-3p LNA has been investigated in other therapeutic areas, including uterine leiomyoma (where it reduces cell proliferation and tumor growth), atherosclerosis (where it promotes plaque stability and mitigates vascular inflammation), and heparin-induced thrombocytopenia.
- Other names
- LNA-anti-miR-148a-3pLNA-anti-miR148a-3pLNA-anti-miR 148a-3panti-miR-148a LNAanti-miR148a LNAanti-miR 148a LNAanti-miR-148a-3p LNAanti-miR148a-3p LNAanti-miR 148a-3p LNAmiR-148a LNAmiR148a LNAmiR 148a LNA
02
Targets
AGO2 (Argonaute RISC catalytic component 2)MAP3K9 (Mixed lineage kinase 1)NRP1 (Neuropilin-1)PRKAA1 (AMP-activated protein kinase alpha catalytic subunit isoform alpha-1)SIK1 (Salt-inducible kinase 1)SMAD2 (Mothers against decapentaplegic homolog 2)SOS2SYK (Spleen Tyrosine Kinase)TXNIP (Thioredoxin-interacting protein)miR-148a-3p (microRNA-148a-3p)
Beyond the preview
Go deeper on miR-148a-3p LNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-148a-3p LNA.